ATARA Biotherapeutics (ATRA): Under The Radar With Catalysts - Jefferies

Jefferies analyst, Maury Raycroft, reiterated his Buy rating on shares of Atara Biotherapeutics (NASDAQ: ATRA) after revisiting the program and considering the opportunity to be intriguing and under-the-radar.

The company recently mentioned that it have additional data from the ATA129 program by YE17 and is likely to start the ATA129 ph.IIIs by YE17. The analyst believes this will catalyze the stock, followed by CMA submission in 2018. No change to the price target of $30.

For an analyst ratings summary and ratings history on Atara Biotherapeutics click here. For more ratings news on Atara Biotherapeutics click here.

Shares of Atara Biotherapeutics closed at $16.95 yesterday.

You May Also Be Interested In

• ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 10c
• Unicycive Therapeutics (UNCY) PT Lowered to $25 at Guggenheim
• Coherent (COHR) PT Raised to $420 at Needham